2012-06-15 09:47:57 - Researchmoz announces a new report "Emerging Pharmaceutical Market in South Africa to 2017 - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process".
Emerging Pharmaceutical Market in South Africa to 2017 - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process
GBI Researchs new report, Emerging Pharmaceutical Market in South Africa to 2017 - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process provides in-depth analysis of the trends, issues and challenges in South Africas pharmaceutical market. The report analyzes the overall pharmaceutical and outsourcing market structure, and provides competitive benchmarking for leading companies. It also analyzes the M&A and strategic partnerships that are shaping the pharmaceutical market. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts.
South Africas pharmaceutical
market is one of the most attractive markets in Africa. Some of the main reasons for its rapid growth are the availability of cost-effective and skilled labor, high quality infrastructure, and the introduction of the South African Health Products Regulatory Authority (SAHPRA). Most of the local drug manufacturers and distributors are in the hands of big international pharmaceutical firms. GBI Research valued the South African pharmaceutical market at $3.8 billion in 2011, and expects it to reach $7 billion in 2018 at a Compound Annual Growth Rate (CAGR) of 9.2%. South Africas healthcare sector is set to witness a number of new healthcare reform plans in the future, with the primary objective being to reduce the growing drug expenditure by increasing the use of generics. The healthcare system aims to cover the entire population under the National Health Insurance (NHI) scheme, which it will start implementing in a small population of 10 districts by 2012.
GBI Researchs analysis shows that generics accounted for over 60% of the volume of the pharmaceutical market in 2011. Government reforms have encouraged the manufacture and use of generic drugs as a tool to limit drug expenditure and provide low-cost effective public healthcare. The combination of government healthcare policies and numerous active generic manufacturing companies points to an increased generic market share in the forecast period.
- Overall pharmaceutical and outsourcing market structure in South Africa
- Market characterization, including market size, major regulatory bodies, pricing and reimbursement issues, major distribution channels, and intellectual property rights
- Contract Research Organization (CRO) market growth
- Analysis of the leading segments within the South African pharmaceutical industry
- Key drivers and restraints impacting the market
- Competitive benchmarking of leading companies in the pharmaceutical and CRO markets in South Africa
- Key M&A activities and strategic partnership deals that took place between 2009 and mid-2011.
Reasons to buy:
- Develop market-entry and market expansion strategies by identifying the leading emerging markets poised for strong growth
- Devise a more tailored country strategy through the understanding of key drivers of and barriers to South Africas pharmaceutical market
- Develop key strategic initiatives by understanding the key focus areas of leading companies
- Accelerate and strengthen your market position by identifying key companies for M&A and strategic partnerships.
For More Information to Buy This Report: